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Atherosclerosis is a chronic inflammatory disease of
arterial wall. Mitochondrial DNA (mtDNA) and human
antimicrobial peptide LL-37 (Cramp in mice) are
involved in atherosclerosis. Recently, mtDNA has
been found to escape from autophagy and cause
inflammation. Normally, mtDNA as an inflammato-
genic factor cannot escape from autophagy and
degradation by DNase II. In this study, we found
elevated amounts of LL37-mtDNA complex in athero-
scleroticplasmaandplaques. Thecomplexwas resis-
tant to DNase II degradation and escaped from auto-
phagic recognition, leading to activation of Toll-like
receptor 9 (TLR9)-mediated inflammatory responses.
Mouse model studies indicated that Cramp-mtDNA
complex aggravated atherosclerotic lesion formation
in apolipoprotein E-deficientmice and antibody treat-
ment against the complex alleviated the lesion. These
findings suggest that the LL-37-mtDNA complex acts
as a key mediator of atherosclerosis formation, and
thus represents a promising therapeutic target.
INTRODUCTION
Human antimicrobial peptide LL-37 (Cramp in mice) can form
complexes with self-DNA and self-RNA in psoriasis. The com-
plexes induce abnormal activation of plasmacytoid dendritic
cells (pDCs) to produce interferon-a (IFN-a) by acting on endoso-
mal Toll-like receptor 9 (TLR9)- and TLR7-residing vesicles,
respectively (Ganguly et al., 2009; Lande et al., 2007). LL-37
has also been identified residing in neutrophil and neutrophil
extracellular traps (NETs) in atherosclerotic lesions (Ciornei
et al., 2006; Cooper et al., 2013; Edfeldt et al., 2006). Additionally,
mouse Cramp forms complexes with self-DNA released from
dying cells or in NETs, breaking the innate tolerance to self-
DNA and triggering direct activation of pDCs, producing IFN-a
and in turn aggravating the formation of atherosclerotic lesionsImm(Do¨ring et al., 2012b). Both nDNA and mtDNA are present in
NETs and dying cells (Keshari et al., 2012; Mun˜oz et al., 2010;
Yousefi et al., 2009), allowing the formation of either LL-37-
nDNA and/or LL-37-mtDNA complexes.
Though the formation of either the nDNA ormtDNA complexes
are possible, whether either can play a similar role, activating leu-
kocytes and promoting atherosclerosis, is not clear. mtDNA con-
tains similar unmethylated CpG repeats to bacterial DNA, while
multiple CpG nucleotides display stronger inflammatogenic
properties than eukaryotic nDNA, which itself contains fewer
such motifs—most of which are masked by methylation (Collins
et al., 2004). Thus, the LL-37-mtDNA complex might display
stronger inflammatogenic properties than LL-37-nDNA. Taken
further, it is not implausible to presume that it is the LL-37-
mtDNA complex—and not the LL-37-nDNA complex—that is
capable of playing the major role in the activation of leukocytes
and promoting atherosclerosis. Here we demonstrate that it is
the LL-37-mtDNA complex that plays a key role to activate
pDCs, neutrophils, and human umbilical vein endothelial cells
(HUVEC) and aggravates atherosclerotic lesion formation by
escaping from DNase II degradation and autophagy.
RESULTS
High Amounts of LL-37-mtDNA Complex Is Found in
Human Atherosclerotic Plasma and Lesions
To support our hypothesis that it is the LL-37-mtDNA complex—
and not the LL-37-nDNA complex—that is capable of playing the
major role in the activation of leukocytes and promoting athero-
sclerosis, we first collected atherosclerotic blood and plaque
samples from patients to investigate whether LL37-mtDNA com-
plex is associated with atherosclerosis. Generally, leukocyte
count serves as a marker of infections and inflammatory ill-
nesses, and more particularly an elevated leukocyte count has
been associated with atherosclerotic disease (Madjid et al.,
2004). In the present study, the amounts of neutrophils
(p = 0.1257) and monocytes (p = 0.0608) in atherosclerotic blood
samples showed no significant differences as compared with
blood samples from normal healthy controls (Figures S1B and
S1C). However, a lower amount of lymphocytes was observed
in atherosclerotic blood (Figure S1D, p < 0.01).unity 43, 1137–1147, December 15, 2015 ª2015 Elsevier Inc. 1137
Figure 1. High Amounts of LL-37, mtDNA, and LL37-mtDNA Complex Are Found in Atherosclerotic Plasma and Plaques
(A) Western blot of LL-37 (or hCAP18) in plasma samples from patients and volunteers. Red Ponceau-stained blot (below) is loading control.
(B) Plasma concentrations of LL-37 in plasma from patients and volunteers were determined by ELISA.
(C) Reverse transcription-qPCR for LL-37 mRNA expression in atherosclerotic lesions (n = 9) and normal vessels (n = 7).
(D and E) Absolute NADH (D) and COX III (E) concentrations were detected by real time-qPCR in patients (n = 59) and volunteers (n = 50).
(F) Plasma concentrations of LL-37-mtDNA in plasma from patients (n = 48) and volunteers (n = 24) were determined by ELISA using anti-LL-37-mtDNA antibody.
(G) Western blot analysis of protein extracts from normal arteries and atherosclerotic lesions using anti-LL-37 and anti-b-actin (loading control) antibodies.
(H) Immunohistochemical analysis of LL-37 (top) and LL-37-mtDNA (bottom) in atherosclerotic plaque and normal vessel. Brown cells are positive for LL-37 or LL-
37-mtDNA complex. Cell nuclei are stained blue with hematoxylin. Neointima (N), vascular lumen (L), and tunica muscularis (TM) are indicated. Scale bar rep-
resents 50 mm.
(I) Atherosclerotic plaque sample and normal artery were labeled with either mousemonoclonal anti-LL-37 antibody (red) or anti-LL-37-mtDNA complex antibody
(FITC-labeled, green) to detect the presence of LL-37 and LL-37-mtDNA complex, and cell nuclei were labeled by DAPI. Arrows indicate LL-37-mtDNA-positive
and LL-37-positive structures. Scale bar represents 20 mm. (H) and (I) Images are representative of at least three independent experiments. Bars represent
mean ± SD. *p < 0.05, **p < 0.01. See also Figure S1.High concentrations of proprotein hCAP18 (18 kDa)—the pre-
cursor of LL-37—were detected in patient’s plasma samples
(Figure 1A). The absolute concentration of LL-37was determined1138 Immunity 43, 1137–1147, December 15, 2015 ª2015 Elsevier Inby using ELISA in patients (63.5 ± 28.9 ng/ml) and healthy volun-
teers (33.6 ± 20.1 ng/ml) (Figure 1B). The mRNA of LL-37 was
elevated 3-fold in the atherosclerosis plaques (Figure 1C).c.
Figure 2. LL-37-mtDNA Is Protected from
DNase II Degradation and Triggers pDC
and PMN Activation
(A) After treatment by DNase II over 60 min, re-
sidual mtDNAs frommtDNA alone, KR-37-mtDNA,
or LL-37-mtDNA were quantified by fluorimetry.
The percentage of protection from DNase II was
calculated as the ratio of remaining mtDNA over
the initial mtDNA input.
(B–F) After stimulation by test sample for 16 hr,
IFN-a in the supernatant of pDC (B), and IL-8 (C),
TNF-a (D), IL-6 (E), and MMP-8 (F) in the super-
natants of PMN were determined by ELISA. Error
bars represent mean ± SD of at least three inde-
pendent experiments. *p < 0.05, **p < 0.01. NC:
0.9% salt water. See also Figures S2 and S3.Further measurement of freemtDNA in the plasma samples of 59
patients and 50 volunteers showed that mtDNA concentration in
patient plasma was3- to 7-fold higher than those in the healthy
controls (Figures 1D and 1E). To detect LL-37-mtDNA, we pre-
pared anti-LL-37-mtDNA complex rabbit polyclonal antibody,
which reacted specifically with the LL-37-mtDNA complex (Fig-
ures S5A and S5B). The concentration of LL-37-mtDNA in pa-
tient plasma was 34.2 ± 26.7 ng/ml, some 2.5-fold higher
than that in healthy individuals (14.6 ± 17.2 ng/ml) (Figure 1F).
Among all the atherosclerotic lesion specimens, high amounts
of LL-37 were also detected in the neointima (Figure 1G and Fig-
ure 1H, top). To determine whether the mtDNA forms a complex
with LL-37 in the plaque of patient specimens, we examined
cellular localization of LL-37-mtDNA complex in plaque. Com-
paredwith the normal tissue, theatherosclerotic lesionsexhibited
a 15-fold increase of LL-37-mtDNA complex (Figure 1H, bottom).
Colocalization of LL-37 and LL-37-mtDNAcomplex in the athero-
sclerotic lesions by immunofluorescence (Figure 1I) furthermore
indicated that LL-37-mtDNA complex is associated with athero-
sclerosis. Collectively, these data indicated that LL-37-mtDNA
complexmightplaya key role inatherosclerotic plaque formation.
LL-37 Protects mtDNA from DNase II Degradation
DNase II is an acid DNase found in the lysosome that plays an
essential role in DNA degradation of apoptotic cells after beingImmunity 43, 1137–1147, Deengulfed by macrophages (Evans and
Aguilera, 2003; Kawane et al., 2006).
Though the underlying mechanisms for
this process are not entirely clear, it might
in part be due to the high concentrations
of mtDNA or LL-37-mtDNA complex.
Here, DNase II activity was found to be
upregulated by 60% in patient plasma
as compared with the healthy control
plasma (Figure S2A). To test the protec-
tive effect of LL-37 onmtDNA fromDNase
II degradation, following incubation with
DNase II for 15 min, the products were
subjected to agarose gel electrophoresis.
LL-37-mtDNA complex was retained in
the loading wells, suggesting that LL-37-
mtDNA complex is resistant to DNase IIdigestion, while mtDNA alone could be easily degraded (Fig-
ure S3). The protective ability of LL-37 onmtDNAwas also quan-
tified by a fluorometric assay. Following 60 min incubation with
DNase II, only 20% mtDNA in LL-37-mtDNA complex was
degraded, whereas over 80% of mtDNA alone or in complex
with control peptide KR-37 was degraded after incubation with
DNase II for only 10 min (Figure 2A). These results imply that
the LL-37-mtDNA complex is likely highly resistant to DNase II
degradation and that LL-37 is a specific protector of mtDNA.
LL-37-mtDNA Complex Triggers pDC and
Polymorphonuclear Leukocyte Activation
pDCs are a unique dendritic cell population highly specialized for
sensing pathogenic single-stranded nucleic acids during viral
and microbial infections (Do¨ring et al., 2012b; Lande et al.,
2007). Both nDNA and mtDNA serve as different types of DNA
sources to form complexes with LL-37, but whether the resulting
LL-37-nDNA and LL-37-mtDNA complexes possess the same
ability to activate pDCs remains unknown. IFN-a secretion
following pDC activation by mtDNA alone, KR-37-mtDNA,
LL-37-nDNA, or LL-37-mtDNA was elevated respectively by
7.5-, 7.6-, 2.5-, and 15-fold, whereas KR-37, LL-37, and
nDNA alone had little effect on pDC activation (Figure 2B).
Among these, LL-37-mtDNA showed much stronger ability to
stimulate IFN-a secretion than LL-37-nDNA.cember 15, 2015 ª2015 Elsevier Inc. 1139
Figure 3. LL-37-mtDNA Strengthens the Formation of Autophagosome but Evades Autophagic Recognition
(A and B) HUVECs were incubated with LL-37, LL-37-nDNA, or LL-37-mtDNA complex for 2 hr to assess formation of autophagosome using LC3 antibody (red).
Cell nuclei were stained by DAPI (blue). Representative image (A) and quantitative result (B) are shown. Scale bar represents 20 mm.
(C) Immunoblot analysis shows increasing concentrations of endogenous LC3-I and LC3-II of HUVECs after stimulation with test samples for 2 hr. b-actin was
probed as the loading control.
(D) Transmission electron microscopy (TEM) images shows autophagic vacuole (arrow) observed in LL-37-mtDNA complex treated HUVECs for 2 hr. N, nucleus;
M, mitochondria. Scale bar represents 0.5 mm.
(E) Confocal microscopy of HUVECs treated for 2 hr with test samples and then cell nuclei and DNA were stained by DAPI (blue); LL-37 and LC3 were stained by
anti-LL-37 (red) and anti-LC3 (green) antibodies, respectively. Arrows indicate LL-37- and LC3-positive structures, while arrowheads represent DAPI- and LL-37-
positive deposits. Scale bar represents 10 mm.
(legend continued on next page)
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PMNs are the most abundant white blood cell in the circula-
tion and play an important role in atherogenesis and plaque
destabilization (Soehnlein, 2012; Weber et al., 2008). The LL-
37-mtDNA complex significantly induced interleukin-6 (IL-6),
IL-8, tumor necrosis factor alpha (TNF-a), andmatrix metallopro-
teinases (MMP)-8 release in purified PMNs (Figures 2C–2F). The
increased concentrations of these four cytokines induced by LL-
37-mtDNA were much higher than those of mtDNA alone or
LL-37-nDNA, indicating that a combination of LL-37 and mtDNA
strengthened the ability of mtDNA to activate PMNs. The effects
of KR-37-mtDNA on these cytokines secretion were not sig-
nificantly different from those of mtDNA alone, indicating
that the control peptide KR-37 has no effect on the ability of
mtDNA to activate PMN. Combined with LL-37-mtDNA’s effects
on pDC activation, these results indicate that the specific com-
plex of LL-37 with mtDNA has a marked ability to activate pDC
and PMN.
LL-37-mtDNA Complexes Escape from Autophagic
Recognition
Autophagy is an evolutionarily conserved and regulated degra-
dation system of cellular response to starvation and stress
(Klionsky and Emr, 2000; Williams et al., 2006). Mounting evi-
dence reveals that autophagy is a key innate defense system
for the elimination of invading cytoplasmic microbes (Deretic
and Levine, 2009). The microtubule-associated protein 1 light
chain 3 (LC3) specifically associates with autophagosomes (Ka-
beya et al., 2000). Here, we noted that the numbers of endoge-
nous LC3-positive vesicles reflecting autophagosomes in human
umbilical vein endothelial cells (HUVECs) were increased after
2 hr-treatment with LL-37, LL-37-nDNA, or LL-37-mtDNA in a
dose-dependent manner (Figures 3A and 3B), with LL-37-
mtDNA showing the strongest ability to stimulate the formation
of LC3 aggregate. The same tendency was also observed in
the amounts of endogenous LC3-I (cytoplasmic form of LC3,
18 kDa) and LC3-II (membrane-bound form of LC3, 16 kDa) by
immunoblot analysis (Figure 3C). The presence of autophago-
some-like vacuole with double-membrane structure from elec-
tron microscopy also confirmed the autophagic activation,
induced by LL-37-mtDNA (Figure 3D).
To elucidate how LL-37-mtDNA complex promotes autopha-
gic responses, the colocalization of LC3 with LL-37-mtDNA
complex was investigated. Figure 3E shows colocalization of
LC3 with LL-37, LL-37-nDNA, or LL-37-mtDNA after 2 hr-treat-
ment in HUVECs. In LL-37-treated HUVECs, most peptide-pos-
itive deposits (red) were associated with LC3 (green), and
following stimulation by LL-37-nDNA, 4’,6-diamidino-2-phenyl-
indole (DAPI)-positive (blue) and LL-37-positive deposits repre-
senting the complex were more frequently associated with
LC3, indicating that both LL-37 and LL-37-nDNA could be
recognized and encapsulated by autophagosomes. However,
by comparison, most of LL-37-nDNA were co-localized with
LC3 (57% ± 13.5%), and only small amounts of LL-37-mtDNA
deposits associated with LC3 (7.8% ± 4.6%) (Figure 3F), sug-(F) The quantitative analysis of percentages of LL-37-DNA deposits associated w
(G) After stimulated for 4 hr with nDNA (Alexa 647 labeled) or mtDNA (Alexa 647 la
were visualized. Confocal images of representative cells are shown. Arrows indic
and G) Images are representative of at least three independent experiments. Ba
Immgesting that the LL-37-mtDNA complex evades autophagic
recognition.
The findings in pDCs also confirmed LL-37-mtDNA complex
escaped from autophagy. As illustrated in Figure 3G, most un-
complexed Alexa Fluor 647-labled nDNA and mtDNA (red)
were associated with LC3 (green, arrows), and even when com-
plexed with LL-37, the LL-37-nDNA complex can also be recog-
nized by autophagosomes (LC3, arrows). In contrast, when
complexed with LL37, mtDNA was entirely distinct from LC3-
positive organelles. Together, these data indicate that LL-37-
mtDNA complex escapes from autophagic recognition.
LL-37-mtDNA Complexes Trigger TLR9 Activation
TLRs detect microbial molecular patterns expressed by patho-
gens and initiate innate and adoptive immune responses. Among
these, TLR9 is originally localized in endoplasmic reticulum (ER),
which then migrates to endosomes when cells are stimulated by
unmethylated microbial DNA, resulting in proinflammatory cyto-
kine secretion (El Kebir et al., 2009; Latz et al., 2004; Sanjuan
et al., 2006). To determine whether TLR9 is involved in recogni-
tion of LL-37-mtDNA complex, the colocalization of TLR9
with LL-37-mtDNA complex in pDCs was investigated. After
pretreatment of pDCs with labeled LL-37-mtDNA complex (the
mtDNA was pre-labelled by Fluor 647), most of the complex
appeared positive for TLR9 (Figure 4A). The IFN-a induced by
LL-37-mtDNA complex in pDCs was specifically inhibited by
the oligonucleotides (ODN)-TTAGGG (Figure 4B), which selec-
tivity block TLR9 signaling. In addition, TLR9-deficient (Tlr9/)
and wild-type (WT) mice were used to examine TLR9-dependent
inflammatory responses in vivo. Compared with the WT mice,
IFN-a induced by mtDNA or Cramp-mtDNA was potently in-
hibited in Tlr9/ mice. When pretreatment of WT mice with
ODN-TTAGGG, the IFN-a production induced by either mtDNA
or Cramp-mtDNA complex was also specifically inhibited (Fig-
ure 4E). Furthermore, Cramp-mtDNA and LL-37-mtDNA com-
plexes were scored positive for TLR9 in the atherosclerotic
lesions in mice and human atherosclerotic plaques, respectively
(Figures 4C and 4D).
Confocal microscopy also demonstrated that, 2 hr after LL-37-
mtDNA stimulation in HUVECs, the number of TLR9-positive
endosome was increased (Figures S4A and S4B). TLR9 proteo-
lytic cleavage within endosomes is a prerequisite for TLR9
signaling, which results in proinflammatory cytokine production
(Park et al., 2008). The same tendency was also observed in
the secretion of chemokines and cytokines (monocyte chemo-
tactic protein [MCP]-1, intercellular cell adhesion molecule
[ICAM]-1, and IL-8) in HUVECs (Figures S4C–S4E), induced by
LL-37, LL-37-nDNA, and LL-37-mtDNA. Both PMNs (Figure 2C)
and HUVECs (Figure S4E) could be induced by LL-37-mtDNA to
release IL-8, which was consistent with the observed high con-
centrations of IL-8 in the plasma of atherosclerotic patients (Fig-
ure S2B). Together, these data suggest LL-37-mtDNA complex
triggers the activation of TLR9 and secretion of chemokines
and cytokines.ith LC3.
beled) alone, or complexed with LL-37, colocalization of DNA and LC3 in pDCs
ate DNA- and LC3-positive structures. Scale bar represents 5 mm. (A, C, D, E,
rs represent mean ± SD. *p < 0.05, **p < 0.01.
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Figure 4. LL-37-mtDNA Triggers TLR9 Acti-
vation
(A) pDCs were stimulated for 4 hr with LL-37-
mtDNA (DNA was labeled by Alexa 647), colocal-
ization of DNA and TLR9 in pDCs were visualized.
Confocal images of representative cells are
shown. Arrows indicate DNA- and TLR9-positive
structures. Scale bar represents 5 mm.
(B) IFN-a produced by pDCs after stimulation
with 0.9% salt water (control), LL-37-nDNA, or LL-
37-mtDNA, or pretreatment with ODN-TTAGGG
(2 mM).
(C) Immunofluorescence staining of Cramp-
mtDNA (green) and TLR9 (red) in the aortic root in
HFD-fed Apoe/ mice. Arrows indicate Cramp-
mtDNA-positive and TLR9-positive structures.
Scale bar represents 200 mm.
(D) Atherosclerotic plaque sample and normal
artery were labeled with either anti-LL-37-mtDNA
complex antibody (FITC-labeled, green) or anti-
TLR9 antibody (red), representative confocal
images were shown. Arrows indicate LL-37-
mtDNA-positive and TLR9-positive structures.
Scale bar represents 200 mm.
(E) Serum concentrations of INF-a in Tlr9/ or
C57BL/6J (WT) mice after treatment with mtDNA
or Cramp-mtDNA complex for 24 hr. Some WT
mice were pre-injected intravenously with ODN-
TTAGGG. Error bars represent mean ± SD of at
least three experiments. *p < 0.05, **p < 0.01. See
also Figure S4.Cramp-mtDNA Complexes Aggravate Atherogenesis in
Apoe–/– Mice
Cramp has been previously observed in vessel wall of diet-fed
Apoe/ mice (Do¨ring et al., 2012b) and the lack of Cramp
reduces atherosclerosis in mice (Do¨ring et al., 2012a). To inves-
tigate whether the Cramp-mtDNA complex is present in athero-
sclerotic lesions in mice, we fed the Apoe/mice a high-fat diet
(HFD) for 4weeks to spark and study the formation of atheroscle-
rosis in the aortic roots. Compared to normal mice,4- and11-
fold increase of free mtDNA (Figure 5A) and Cramp-mtDNA
complex (Figure 5C) were observed in the plasma of disease
mice, respectively. Cramp mRNA expression (Figure 5B) and
mature Cramp peptide (Figure 5D, top) in mouse atherosclerotic
lesions was about 6 and 23 times of that in normal tissue, respec-
tively. Immunohistochemical analysis using anti-Cramp-mtDNA
complex antibody (Figures S5C and S5D) also showed a
significantly higher amount of Cramp-mtDNA complex in athero-
sclerotic plaque (brown) in high-fat diet-fed Apoe/ mice
(Figure 5D, bottom). Furthermore, we used 5-ethynyl-29-deoxy-
uridine (EdU), a nucleoside analog to thymidine to label mtDNA in
atherosclerotic lesions of Apoe/ mice, and the EdU-and
Cramp-positive deposits representing the complexes were
observed, indicating that Cramp-mtDNA complex accumulated
in atherosclerotic lesion (Figure 5E).
To further clarify the role of Cramp-mtDNA complex in the
pathogenesis of atherosclerosis, the complex or controls were
injected into Apoe/ mice to assess atherosclerotic lesion
sizes in aortic root sections. As illustrated in Figure 5F, the size1142 Immunity 43, 1137–1147, December 15, 2015 ª2015 Elsevier Inof atherosclerotic lesion represented by oil-red positive area in
the aortic root was markedly increased by Cramp-mtDNA injec-
tion (24.8%) into Apoe/ mice, compared with that of GK-33
(2.3%), Cramp (6.2%), mtDNA (7.5%), nDNA (2.5%), or Cramp-
nDNA (5.5%) injection. The concentrations of inflammatory
cytokines (Figure S6) furthermore indicate that Cramp-mtDNA
complex drives atherosclerotic plaque development.
Given that high concentrations of LL-37-mtDNA complex are
in atherosclerotic plasma and plaque, and Cramp-mtDNA can
induce atherosclerosis, we hypothesized that the antibody
against LL-37-mtDNA might exert anti-atherosclerosis effect.
To prove the hypothesis, we subjected the Apoe/ mice to a
HFD for 5 weeks, together with receiving an anti-Cramp-mtDNA
antibody (Ab2) or an isotype control antibody (immunoglobulin
G, IgG) treatment. Confocal microscopy revealed that the fluo-
rescein isothiocyanate (FITC)-labeled anti-Cramp-mtDNA anti-
body specifically localized in vivo with Cramp but was distinct
from Cramp-nDNA complex (Figure 6A). Because most EdU-
labeled deposits representing mtDNA appeared positive for
Cramp (Figure 5E), thus the colocalization of Cramp-mtDNA anti-
body and Cramp indicated that the injected Cramp-mtDNA anti-
body is specifically binding to Cramp-mtDNA complex in vivo in
Apoe/ mice treatment. After a 5-week treatment, an obvious
decrease in plaque size was observed in Cramp-mtDNA anti-
body treated Apoe/ mice compared with control IgG-injected
Apoe/ mice (Figures 6B and 6C). The reduction in plaque size
was associated with the reduction in serum concentrations of
Cramp-mtDNA complex (Figure 6D), TNF-a (Figure 6E), IL-6c.
(Figure 6F), and IFN-a (Figure 6G) in Cramp-mtDNA antibody
treated Apoe/ mice compared with control IgG-injected
Apoe/ mice. Together, these data clearly indicate that the
Cramp-mtDNA complex drives development of atherosclerotic
plaques and that interference with the complex might harbor
valuable opportunities for atherosclerosis prevention and
treatment.
DISCUSSION
Dying host cells, inflammatory cells, and NETs released by acti-
vated neutrophils at the sites of infection and acute inflamma-
tion (Beiter et al., 2006; Brinkmann et al., 2004; Buchanan et al.,
2006; Do¨ring et al., 2012b) are rich sources of both nDNA and
mtDNA (Marichal et al., 2011; Ganguly et al., 2009; Yousefi
et al., 2008). The released RNA and DNA trigger activation of
DCs by forming complexes with LL-37 (Ganguly et al., 2009;
Lande et al., 2007). Though nuclear and mitochondrial DNA
are contained in NETs and dying cells (Keshari et al., 2012; Mu-
n˜oz et al., 2010; Yousefi et al., 2009), they each display different
inflammatory properties as a result of unmethylated CpG motifs
present in mtDNA. In this study, we found that mtDNA in com-
plex with LL-37 caused primary autoimmune activation and
aggravated atherosclerotic lesion formation by escaping from
self-clearing (DNase degradation and autophagy) and acti-
vating TLR9 signaling.
Complex amplification of inflammatory cascades is critically
involved in the formation of atherosclerotic lesion. The athero-
sclerotic process is typically initiated by endothelial dysfunction
and structural alterations, leading to an increased uptake,
entrapment, and deposition of lipids, especially low-density lipo-
protein (LDL) (Kwon et al., 2008). By triggering expression of
adhesion molecules and chemokines in endothelial cells,
oxidized LDL (oxLDL) particles promote leukocyte-endothelial
interactions (Weber and Noels, 2011). Our present results
demonstrate that LL-37-mtDNA exacerbates inflammation by
stimulating IFN-a production in pDCs, and inducing IL-6, IL-8,
TNF-a, and MMP-8 release in PMN. IFN-a intensifies TNF-a,
IL-12, and MMP-9 production and threaten the stability of in-
flamed atherosclerotic plaque (Niessner et al., 2007). Meanwhile,
IL-6 plays a major role in atherosclerosis pathogenesis (Ikeda
et al., 1991; Boring et al., 1998), while IL-8 causes PMN chemo-
taxis and activation, and activated PMN is capable of releasing
IL-8 in response (Zhang et al., 2010). TNF-a has been suggested
to play an important role in atherosclerosis development (Willer-
son and Ridker, 2004; Zhang et al., 2014). Releasing MMP-8 is a
marker of PMN degranulation, and it is involved in PMN penetra-
tion and recruitment (Zhang et al., 2010). Accordingly, by trig-
gering pDC and PMN activation to release these chemokines
or cytokines, LL-37-mtDNA serves as inflammatory amplifier
that is capable of attracting more PMNs to infiltrate atheroscle-
rotic lesions.
PMNs are not the only type of white blood cells to infiltrate
atherosclerotic plaque in process of atherosclerotic lesion for-
mation; indeed, monocytes are another kind of leukocyte
recruited to arterial intima that plays a role in engulfment of
lipids, and transformation into macrophage foam cells (Libby
et al., 2011). Endothelial cells are activated to express MCP-1
and ICAM-1 to capture monocytes when they are subjectedImmto irritative stimuli. Previous studies demonstrate that MCP-1
and ICAM-1 are upregulated in human atherosclerotic lesions
and have been implicated in the formation and progression of
atherosclerotic lesions (Bourdillon et al., 2000; Koyanagi
et al., 2000). Our results show that LL-37-mtDNA stimulated
endothelial cell HUVECs to produce MCP-1, ICAM-1, and
IL-8 (Figures S4C–S4E), suggesting that LL-37-mtDNA serves
as a key mediator to attract monocytes to atherosclerotic
plaque.
The released TNF-a and MMP-8 influence endothelial perme-
ability, thus promoting entry of LDL and leukocytes to the
artery wall. Concurrently, some molecules or complexes might
then be released into circulation system from the necrotic
core of atherosclerotic plaque. Here, elevated concentrations
of LL-37, mtDNA, and LL-37-mtDNA complex were found in
atherosclerotic plasma. High concentration of LL-37-mtDNA
was also observed in the neointima of the human atheroscle-
rotic lesion or Cramp-mtDNA in atherosclerotic arteries of
Apoe/ mice, suggesting that the LL-37-mtDNA complex is
associated with atherosclerotic plaque formation. Injection of
Cramp-mtDNA into HFD-fed Apoe/ mice significantly pro-
moted atherosclerotic plaque growth while administration
of an anti-Cramp-mtDNA antibody led to a substantial reduc-
tion of atherosclerotic plaque size in Apoe/ mice. In
aggregate, the data indicate that mtDNA in complex with LL-
37 or Cramp promotes atherosclerosis, and therapeutic deple-
tion of the complex might potentially inhibit atherosclerosis
progression.
Given that LL-37-mtDNA acts as an inflammatory stimulator,
it might be distinguished by autophagosome or endosome,
and subsequently delivered to the lysosome for degradation.
Although LL-37-mtDNA strengthened the formation of auto-
phagosome, it escaped from autophagic recognition. The
increasing formation of autophagosome might result from
TLR9 activation induced by LL-37-mtDNA, as TLRs agonists
have previously been demonstrated to induce high amount
of autophagosome formation (Delgado and Deretic, 2009).
In addition, due to the protection by LL-37, mtDNA might
not be degraded or its degradation might be delayed by
DNase II or autophagy in vivo, leading to continuous activation
of TLR9.
Taken together, these lines of evidence in the present study
indicate that by forming a complex with LL-37, the endogenous
mtDNA from NETs and dying cells in atherosclerotic plaque are
protected from DNase II and autophagy degradation, which
leads to persistent activation of TLR9. The indelible autoimmune
activation and generation of chemokines or cytokines eventually
aggravate atherosclerosis lesion. These data provide new per-
spectives on the mechanism of genesis of chronic inflammation
that accompanies atherosclerosis, potentially providing a prom-
ising new therapeutic target.
EXPERIMENTAL PROCEDURES
The Institutional Review Board of Kunming Institute of Zoology (KIZ) and
Kunming Yanan Hospital approved this study (syxk2012-0039, YAH2012-
0018). All human specimens were collected with the informed consent of the
patients prior to the study. All animal experiments were approved by the Ani-
mal Care and Use Committee at Kunming Institute of Zoology (SYDW-
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Figure 5. Cramp-mtDNA Complex Is Associated with Atherosclerotic Lesion Formation in Apoe–/– Mice
(A) RelativemtDNA copy number in plasma of HFD fed or healthyApoe/mice determined by RT-qPCR. The relativemtDNA copy number was normalized to the
single-copy nuclear Hbb gene.
(B) Cramp mRNA relative expression in plaque of HFD fed atherosclerotic (Apoe/+HFD) and healthy Apoe/ mice (Apoe/) determined by RT-qPCR. The
relative mRNA expression levels of Cramp were normalized by Gapdh.
(C) The serum concentration of Cramp-mtDNA complex in the HFD fed atherosclerotic (Apoe/+HFD) or healthyApoe/mice (Apoe/) was detected by ELISA
using anti-Cramp-mtDNA antibody.
(D) Immunohistochemical analysis of Cramp (upper) and Cramp-mtDNA (bottom) in plaques of atherosclerotic Apoe/ mice and healthy mice vessels, and
the responding quantitative analysis of the stained area are shown in right panel (n = 5). Representative images of aortic root are shown. Scale bar
represents 50 mm.
(legend continued on next page)
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Figure 6. Antibody Against Cramp-mtDNA Exerts Anti-atherosclerosis Effect in Mice
(A) Apoe/ mice were fed a HFD, together with receiving a FITC-labeled anti-Cramp-mtDNA antibody for 3 weeks, representative localization images of the
antibody (green) with Cramp (red) or Cramp-nDNA (red) in aortic root are shown. Scale bar represents 20 mm. Apoe/ mice were fed a HFD over 5 weeks and
treated with a control immunoglobulin G (HFD+IgG) or anti-Cramp-mtDNA antibodies (HFD+Ab2).
(B–G) Representative images of oil red O-stained plaques (B) and quantitative analysis (C) of stained area are shown. Serum concentration of Cramp-mtDNA
complex (D) and TNF-a (E), IL-6 (F), and INF-a (G) in the atherosclerotic mice during the antibodies’ treatment are shown. Data are representative of at least five
independent experiments. Error bars represent mean ± SD. *p < 0.05, **p < 0.01. WK, week. See also Figure S6.Peptides Synthesis
LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) and a scrambled
control peptide KR-37 (KRKSFDGFKELILKGRQEIKFKRDIFLVNLRETRPSV)
and Cramp (GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE) and a corre-(E) Three staining of aortic root in HFD-fed Apoe/mice with DAPI (blue), EdU (gr
positive structures. Scale bar represents 20 mm.
(F) Apoe/ mice receiving a HFD were treated with test sample for 4 weeks, rep
(bottom) of stained area are shown. (D) and (E) Images are representative of at leas
bars represent mean. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5.
Immsponding scrambled control peptide GK-33 (GKLGIKERLGPGEEQKKLPVN
FKFQKIKQIGLK) were synthesized by GL Biochem (Shanghai, China) and
analyzed by reversed phase high-performance liquid chromatography (RP-
HPLC) and mass spectrometry to confirm their purity higher was greater 98%.een), and anti-Cramp antibody (red). Arrows indicate EdU-positive and Cramp-
resentative images (top) of oil red O–stained plaques and quantitative analysis
t five independent experiments. (A–C) Error bars represent mean ± SD; (F) Error
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Preparation of nDNA and mtDNA
A mitochondrial DNA and nuclear DNA isolation kit for cultured cells (Genmed
Scientifics) was used to isolate DNAs from human embryonic kidney 293 cells
(HEK293). DNA concentration was determined using a spectrophotometer.
None of the DNA showed evidence of protein contamination, and neither
nDNA nor mtDNA was contaminated by one another. The mtDNA and nDNA
were labeled with Alexa 647 using the ULYSIS Nucleic Acid Labeling Kits
(Molecular Probes) according to the protocol provided by the manufacturer
in pDCs stimulation experiments.
Nuclease Protection Assays
mtDNA, KR-37-mtDNA, or LL-37-mtDNA complex were treated with DNase II
at 37C in 0.1 M sodium acetate buffer (pH 4.7) containing 20 mM EDTA,
respectively. DNase II digested mtDNA was quantified by fluorimetry using
PicoGreen (Invitrogen) at different time points. Intact and mtDNA treated by
DNase II were then run on a 1% agarose gel and visualized by ethidium bro-
mide staining. For generation of LL-37- mtDNA complex and KR-37-mtDNA
complex, 20 mg of peptide was mixed with 4 mg DNA in 20 ml of PBS
(1.5 mM KH2PO4, 2.7 mM Na2HPO4$7H2O, 0.15 M NaCl, pH 7.4), and incu-
bated for 15 min at room temperature according to a previously described
method (Ganguly et al., 2009).
Mouse Models
Apoe/, Tlr9/, and C57BL/6J mice were purchased from Vitalriver exper-
iment animal company. The Apoe/ mice (female, 7–8 weeks old) were fed
an atherogenic diet (HFD, 21% fat, 0.15% cholesterol, Altromin). Some
Apoe/ mice were injected intravenously (i.v.) with GK-33 (100 mg/mouse),
Cramp (100 mg/mouse), mtDNA (20 mg/mouse), nDNA (20 mg/mouse),
Cramp-nDNA complex (120 mg/mouse), or Cramp-mtDNA complex
(120 mg/mouse) 3 times per week for 4 weeks (Do¨ring et al., 2012b; Ganguly
et al., 2009). Some Apoe/ mice were i.v. injected with anti-Cramp-mtDNA
complex antibody (or FITC-labeled anti-Cramp-mtDNA complex antibody)
(50 mg/mouse) or an isotype control antibody (BioXcell, 50 mg/mouse) twice
a week for 5 weeks. 1 week before detected, some Apoe/ mice were in-
jected intraperitoneally with 250 mg of EdU every 2 hr five times (Oka
et al., 2012) to label mtDNA in mice. Tlr9/ and C57BL/6J (WT) mice
were injected intravenously with mtDNA (20 mg/mouse) or Cramp-mtDNA
complex (120 mg/mouse) to study TLR9-dependent inflammatory responses.
Some WT mice were pre-injected intravenously with ODN-TTAGGG
(20 mM/mouse).
Specimens of Human Atherosclerotic Plaque and Blood
All human specimens were collected with the informed consent of the
patients prior to the study. In total, 59 with coronary heart disease who
had angiographically visible luminal narrowing (26%–45%) were selected
in present study. None of these patients had a history of myocardial infarc-
tion and were 41–85 years old (Figure S1A). The 59 patients were matched
with 50 healthy volunteers with angiographically normal coronary arteries,
and no history of hypertension, diabetes mellitus, or hypercholesterolemia
disease, who served as normal control group. Blood samples were collected
from both patients and volunteers. Total and differential leucocyte counts
(neutrophils, monocytes, lymphocytes) in whole blood samples (Figures
S1B–S1D) were determined using automated particle counters (Sysmex,
XE-2100).
Atherosclerotic plaque samples were obtained from patients undergoing
carotid endarterectomy, and normal control arteries were obtained from
patients undergoing coronary artery bypass surgery. Immediately following
surgical removal, some samples were placed in RNAlater (QIAGEN) for
RNA extraction; others were fixed in 10% neutral phosphate buffered
formalin to await further use, or minced and homogenized at 4C for protein
extraction.
Statistical Analyses
For statistical analysis, data obtained from independent experiments were
presented as mean ± SD. All statistical analyses were two-tailed, with 95%
confidence intervals (CI), and conducted using GraphPad prism 4. Results
were analyzed using an unpaired t test. Differences were considered signifi-
cant when p < 0.05.1146 Immunity 43, 1137–1147, December 15, 2015 ª2015 Elsevier InSUPPLEMENTAL INFORMATION
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